Applied DNA Sciences, Inc.

296 articles with Applied DNA Sciences, Inc.

• Applied DNA Provides Preliminary Estimated Fiscal Second Quarter 2021 Revenue Range and Business Update

  4/21/2021

  - Anticipates Revenues in the Range of $2.5 Million to $2.7 Million Driven by COVID-19 Testing and Diagnostics Sales - - Announces Full Loan Forgiveness under Paycheck Protection Program – - NYS Department of Health Completes Re-Inspection of ADCL -

• Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

  4/8/2021

  Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

• Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

  4/7/2021

  - Offers Valuable Real-Time Surveillance of SARS-CoV-2 Mutations and VoCs-  - Program Powered by Applied DNA’s Mutation-targeted qPCR Assays and NGS Platform - - Program Data Potentially Relevant to COVID-19 Vaccine and Therapeutics Developers, Precision Medicine -

• Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

  4/1/2021

  - Shorrock Rejoins Company; Appointment Underscores Company’s Pursuit of Commercial Activities In Highly Regulated End-Markets, Including Biotherapeutics and Diagnostics -

• Applied DNA Receives Blanket Purchase Order for Linea™ COVID-19 Assay Kits for 10,000 Tests

  3/11/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the receipt of a purchase order for its Linea™ COVID-19 Assay Kit (the “Assay Kit”) and consumables to conduct 10,000 tests under a Master Services Agreement with an existing customer.

• Applied DNA Launches Linea™ COVID-19 Selective Genomic Surveillance™ Mutation Panel to Boost SARS-CoV-2 Variant Detection and Tracking Nationally

  3/9/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the launch of its Linea™ COVID-19 Selective Genomic Surveillance™ (SGS) Mutation Panel (the “SGS Panel”) to enhance the utility of limited Next Generation Sequencing

• Applied DNA to Participate in Upcoming Conferences

  3/8/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, will be participating in the following virtual investor conferences.

• Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market

  3/2/2021

  - Vaccine Candidate Previously Demonstrated Antibodies and T-cell Response in Mouse Models - - Clinical Trial to Serve as Initial Validation of LinearDNA Platform in Large Mammals with Potential Advantages in Manufacturing, Storage, and Distribution over Other Vaccines -

• Applied DNA to Provide Back-To-Campus COVID-19 Surveillance Testing to LIM College

  2/19/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and LIM College, a midtown Manhattan-based leader in education for the business of fashion, today announced that Applied DNA will provide COVID-19 surveillance testing for all in-person students

• Applied DNA Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range

  2/11/2021

  – Reports Revenues of $1.6 Million Compared with $634,000 in the Year-Ago Period and $314,000 in the Fourth Quarter of Fiscal 2020 – - Leverages EUA-Authorized Assay’s Ability to Discriminate for Certain SARS-CoV-2 Variants to Pursue Market for Genomic Surveillance, Receives Initial Orders –

• Applied DNA Schedules Fiscal 2021 First Quarter Financial Results Conference Call and Webcast for Thursday, February 11, 2021

  2/5/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2021 first quarter financial results after market close on Thursday, February 11, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day.

• Applied DNA Achieves Program Milestone in Development of Linear DNA Veterinary COVID-19 Vaccine

  2/2/2021

  – Qualifies Freeze-Dried Version of LinearDNA ™ COVID-19 Vaccine Candidate Ahead of Initiation of Feline Clinical Trial – –  Reconstituted Vaccine Candidate Demonstrates Potency, Validating Easy Shipment in Dry State – – Feline Clinical Trial On-Track to Begin by March 31, 2021 –

• Applied DNA Provides Business Update on COVID-19 Diagnostics and Testing

  1/15/2021

  - Average Daily Testing in January 2021 to Date Up 158% Over December 2020, Driven Primarily by Scale Up in Testing Contracts - - Company Increases Production of Assay Kits (Tests) and Sample Collection Kits to Meet Further Demand -

• Applied DNA Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  1/13/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered direct offering with a group of institutional investors of 1,810,000 shares of common stock at a price of $8.30 per share

• Applied DNA Announces Pricing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  1/11/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,810,000 shares of common stock at a price of $8.30 per share, priced at-the-market under Nasdaq rules,

• U.S. FDA Lists Applied DNA’s Linea™ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7)

  1/8/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) published a safety communication (the “Communication”) that identifies the Company's Linea Assay Kit

• Applied DNA to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference

  1/5/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that Dr. James A. Hayward, president and CEO, will participate in a fireside chat at the virtual H.C. Wainwright BIOCONNECT 2021 Conference to be held January 11-14, 2021. The fireside chat will be hosted by Yi Chen, Managing Director, H.C. Wainwright Equity Research, and Applied DNA co

• Applied DNA Announces Preliminary Estimated First Fiscal Quarter 2021 Revenues in the Range of $1.3 Million to $1.6 Million

  1/4/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it expects revenues for the first fiscal quarter of 2021 ended December 31, 2020, to be in the range of $1.3 million to $1.6 million compared to revenues of $314,000 in the fourth quarter of fiscal 2020.

• Applied DNA Partners with CLEARED4 on Pooled COVID-19 Surveillance Testing Program

  12/29/2020

  – Applied DNA’s safeCircle™ Program Integrates with CLEARED4 Digital Platform for Online Health Safety Management and Reporting, Option Geared for Scaling of High-Volume Testing Clients –

• Applied DNA Reports 2020 Year End and Fiscal Fourth Quarter Financial Results

  12/17/2020

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2020.